Printer Friendly
The Free Library
19,573,962 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

3M Drug Delivery Systems and MicroDose Technologies Inc. Team Up to Bring Advanced Electronic Dry Powder Inhaler Technology to Market.


ST. PAUL St. Paul

as a missionary he fearlessly confronts the “perils of waters, of robbers, in the city, in the wilderness.” [N.T.: II Cor. 11:26]

See : Bravery
, Minn. -- Collaboration will Provide Fully Integrated Drug Delivery Solutions for the Pharmaceutical and Biotechnology Industries

3M and MicroDose Technologies Inc., a privately held drug delivery company based in Monmouth Junction, N.J., announced today that the two companies have entered into an exclusive co-development and joint marketing agreement. The collaboration will combine MicroDose's leading edge dry powder inhaler The Dry Powder Inhaler is generally a proprietary device to deliver medications for the treatment or maintenance management of respiratory diseases and conditions. These conditions or diseases may include Asthma, Bronchitis, Emphysema, COPD and Diabetes.  technology with 3M's global inhalation product development, formulation development (particle engineering and powder handling), and manufacturing capabilities. As part of the deal, 3M has invested $5 million for a minority equity position in MicroDose.

"Collaborating with MicroDose and its strong technology platform in dry powder Dry Powder

A slang term for cash reserves kept on hand to cover future obligations.

Notes:
For example, if a venture capitalist expects bad times in the IPO markets you might hear him say something like, "we want to keep enough dry powder around to keep funding our
 inhalation will significantly enhance 3M Drug Delivery Systems Division's capability to provide partner pharmaceutical and biotechnology companies Top 100 Biotechnology Companies
The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies.
 with innovative drug delivery solutions. We are excited to add to the unique breadth and depth of technology that 3M is able to deliver to our customers," said John Sampson John Sampson is the name of:
  • John A. Sampson (1873–1946), American gynecologist and medical researcher
  • John L. Sampson (born 1965), New York state senator
, division vice president, 3M Drug Delivery Systems Division. He added, "As we considered potential partners offering next generation technologies, MicroDose clearly stood out with a proven, customer-focused approach that enables flexibility to meet customer requirements with inhalation technology that is truly revolutionary."

The MicroDose Dry Powder Inhaler (DPI (Dots Per Inch) The measurement of the resolution of display and printing systems. A typical CRT screen provides 96 dpi, which provides 9,216 dots per square inch (96x96). Flat panel displays from 110 to 200 dpi have also been developed. ) is among a number of key proprietary technology platforms developed by MicroDose. The MicroDose DPI is a handheld, low-cost, breath-activated device that utilizes piezo "Piezo", derived from the Greek piezein, which means to squeeze or press, is a prefix used in:
  • Piezoelectricity
  • Piezometer
  • Piezo ignition
  • Piezoelectric sensor
  • Piezoelectric loudspeakers
 electronics to efficiently deliver a broad range of compounds. Such compounds include small or large molecule therapeutics for both local and systemic applications. The device promises to be the first completely electronic DPI on the market and represents the next generation in inhaler inhaler /in·hal·er/ (in-hal´er)
1. an apparatus for administering vapor or volatilized medications by inhalation.

2. ventilator (2).


in·hal·er
n.
 technology both in performance and ease of use for patients.

Commenting on the transaction, Anand Gumaste, president and chief executive officer, MicroDose, said, "Through this collaboration, MicroDose is able to offer the pharmaceutical and biotechnology industries a fully integrated inhalation product development and manufacturing capability. We are pleased to be partnering with 3M to make this happen."

Scott Fleming, senior vice president of marketing, MicroDose, added "By combining our innovative inhaler technology platform with 3M's proven leadership in health care products and strong brand, we will create a dynamic partnership providing unique inhalation product solutions for an expanded market."

MicroDose and 3M currently are seeking business alliances with pharmaceutical and biotechnology companies interested in the pulmonary delivery of their molecules.

About MicroDose Technologies Inc.

MicroDose Technologies Inc., based in Monmouth Junction, N.J., is a leading privately held drug delivery company, developing advanced pulmonary, combination solid oral dosage, and other technologies for the pharmaceutical and biotechnology industries. The MicroDose DPI has been licensed to Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were  Co. for the delivery of inhaled in·hale  
v. in·haled, in·hal·ing, in·hales

v.tr.
1. To draw (air or smoke, for example) into the lungs by breathing; inspire.

2.
 insulin and is currently in development. MicroDose is also co-developing, with the University of Pittsburgh, an inhaled delivery system for a nerve agent Noun 1. nerve agent - a toxic gas that is inhaled or absorbed through the skin and has harmful effects on the nervous and respiratory system
nerve gas

agent - a substance that exerts some force or effect
 antidote for the U.S. Department of Defense. In addition, MicroDose has several collaborations ongoing with undisclosed major pharmaceutical partners in the respiratory market segment.

About 3M Drug Delivery Systems -- Part of the 3M Health Care Family

3M Health Care, the largest of seven major 3M businesses, is dedicated to improving the practice, delivery and outcome of care in medical, dental, pharmaceutical, health information and personal care markets. 3M Drug Delivery Systems Division, part of the 3M Health Care family, is a global leader in the development of inhalation and transdermal technologies. As the creator of the first metered-dose inhaler metered-dose inhaler Pharmacology A device used to deliver a specified number of doses of a therapeutic inhalant–eg, β-agonist for asthma , the division's history spans more than 50 years of medical innovation as a true pioneer of these technologies in both components as well as total drug delivery systems. Additional information is available at www.3M.com/dds.

About 3M -- A Global, Diversified Technology Company

Every day, 3M people find new ways to make amazing a·maze  
v. a·mazed, a·maz·ing, a·maz·es

v.tr.
1. To affect with great wonder; astonish. See Synonyms at surprise.

2. Obsolete To bewilder; perplex.

v.intr.
 things happen. Wherever they are, whatever they do, the company's customers know they can rely on 3M to help make their lives better. 3M's brands include icons such as Scotch, Post-it, Scotchgard, Thinsulate, Scotch-Brite, Filtrete, Command and Vikuiti. Serving customers in more than 200 countries around the world, the company's 67,000 people use their expertise, technologies and global strength to lead in major markets including consumer and office; display and graphics; electronics and telecommunications; safety, security and protection services; health care; industrial and transportation. For more information, including the latest product and technology news, visit www.3M.com.

Scotch, Post-it, Scotchgard, Thinsulate, Scotch-Brite, Filtrete, Command and Vikuiti are trademarks of 3M.
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jul 19, 2004
Words:728
Previous Article:Bank Services of Virginia Updates Check Processing Systems, Selects VSoft's eDesk; eDesk Offers Fraud Protection and Increased Operational...
Next Article:Geospatial Software Vendors Declare OGC Plugfest a Success.



Related Articles
Asthma drug may do more harm than good.
NEW INFLUENZA DRUG TESTED ON THE ELDERLY; 3 RESIDENTS OF RESEDA HOME UNDERGO FIRST TRIAL.
Nicotine inhalation system (Nicotrol inhaler). (Medication Update).
BRITANNIA TO DEVELOP NASAL POWDER FOR MIGRAINE SUFFERERS.
INSULIN INHALER TESTS NEARING A FINAL PHASE GIANT LEAP FOR MANNKIND.
FIRM IN NASDAQ BIOTECH INDEX LOCAL MANNKIND CORP. CHOSEN FOR LISTING.
INHALED-INSULIN TESTS PLANNED MANNKIND CORP. ENROLLING PATIENTS IN PHASE 3 SAFETY TRIAL.
Otsuka Pharmaceutical to Introduce New Dosage Form for Its bronchodilator Meptin.
ZELOS/NEKTAR START PHASE 1 TRIAL OF INHALED OSTABOLIN-C.
US FAST-TRACKS PHARMAXIS CYSTIC FIBROSIS DRUG.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles